Table 7.
Plant-derived bioactive compounds with neuroprotective effects in PAD.
| Neuroprotective-Based Activity | |||||||
|---|---|---|---|---|---|---|---|
| Plant | Bioactive Compound | Reduction α-Synuclein | OS Reduction | Antioxidant | DA Levels | Proteasomal Activation | Refs. |
|
Scutellaria baicalensis (dose 25–100 µM/SH-Sy5Y cell culture) |
Baicalein | [89] | |||||
|
Erythrina velutina (dose 25 µg/mL/SH-SY5Y cell culture) |
Sigmoidin A and B, erycristagallin, abyssinone V-4′-methyl ether, waragalone, mildbenone, 2″-O-galloyl orientin, neobavaisoflavone, and hypaphorine | X | X | [90] | |||
|
Peganum harmala (dose 300–600 mg/kg mice) |
Harmalol, harmaline, and harmine | X | X | [92] | |||
| Carthamus tinctorius (dose 10 mg/kg rats) | Kaempferol, hyperoside, naringenin, quercetin, and luteolin | X | X | [93] | |||
|
Pueraria lobata (dose 25 or 50 mg/kg rats) |
Puerarin | X | X | [94] | |||
| Ginkgo biloba | Ginsenosides | X | X | X | [95] | ||
|
Hypericum perforatum (dose 200 mg/kg rats) |
Naphthodianthrones and phloroglucinols | X | X | [96] | |||